Co-Diagnostics,Completes Updated Clade Ib Analysis Of 2-Gene Mpox RUO Test; Results Show That Test Should Retain Full Reactivity Against Mpox Strains Circulating Over The Last Year, Including 1b.
Portfolio Pulse from Benzinga Newsdesk
Co-Diagnostics has completed an updated analysis of its 2-Gene Mpox RUO Test, confirming that the test retains full reactivity against Mpox strains, including Clade 1b, circulating over the past year.
September 05, 2024 | 1:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Co-Diagnostics' updated analysis of its 2-Gene Mpox RUO Test shows it retains full reactivity against recent Mpox strains, including Clade 1b. This could enhance the test's marketability and reliability.
The confirmation that Co-Diagnostics' test remains effective against current Mpox strains, including Clade 1b, suggests the product is reliable and up-to-date, potentially increasing demand and positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90